
<!DOCTYPE html>

<html lang="en">
<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/cs.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [];
		
	</script>
</head>
<body class="slide-ref">

<div id="popup"> 
<ol>
<li><span>KALETRA [package insert].</span></li>
<li><span>Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus<br>twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management<br>of antiretroviral naïve HIV-1-infected patients: 48-week efficacy and safety results of the CASTLE<br>study. <em>Lancet</em>. 2008;372:646-655.</span></li>
<li><span>Molina JM, Andrade-Villanueva J, Echevarria J, et al; for the CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir<br>and emtricitabine, for management of antiretroviral naïve HIV-1–infected patients: 96-week efficacy<br>and safety results of the CASTLE study. <em>J Acquir Immune Defic Syndr</em>. 2010;53:323-332.</span></li>
<li><span>National Heart, Lung, and Blood Institute website. ATP III guidelines at-a-glance quick desk<br>reference. National Cholesterol Education Program. Available at: http://www.nhlbi.nih.gov/ guidelines/cholesterol/atglance.pdf. Accessed July 28, 2010.</span></li>
<li><span>Dubé MP, Stein JH, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia in<br>human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations<br>of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS<br>Clinical Trial Group. <em>Clin Infect Dis</em>. 2003;37:613-627.</span></li>



</ol>



</div>

</body>
</html>

 
